Longeveron publishes Phase 2b stem cell trial results in Cell Stem Cell Feb 25, 2026 11:05AM
Longeveron receives Japan patent for stem cell potency testing methods Jan 29, 2026 09:15AM
Longeveron receives Canadian patent for stem cell treatments Dec 2, 2025 09:15AM
Longeveron presents MRI data on stem cell therapy for Alzheimer's Dec 1, 2025 12:02PM
Longeveron selected for Alzheimer's poster at CTAD 2025 conference Nov 19, 2025 09:15AM


Nov 5, 2025 06:24AM Longeveron (LGVN) Reports Q3 Loss of $0.39
Nov 5, 2025 06:21AM Longeveron (LGVN) reports Q3 result
Sep 3, 2025 04:05PM Longeveron appoints Than Powell as interim CEO, Joshua Hare as chairman
Jul 21, 2025 09:15AM Longeveron licenses stem cell patent from University of Miami
Jul 8, 2025 09:15AM Longeveron gets FDA approval for pediatric heart disease trial
Jun 26, 2025 09:05AM Longeveron (LGVN) Appoints Than Powell as Chief Business Officer
Jun 24, 2025 06:31AM Longeveron (LGVN) Completes Enrollment of Pivotal Phase 2b Trial of Laromestrocel
May 8, 2025 07:22PM Longeveron (LGVN) Misses Q1 EPS by 12c
Apr 22, 2025 04:06PM Longeveron (LGVN) CEO issues letter to shareholders
Mar 28, 2025 04:09PM Longeveron (LGVN) Files $70M Mixed Shelf
Mar 20, 2025 09:00AM Longeveron (LGVN) Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel in Alzheimer’s Disease
Mar 11, 2025 08:31AM Longeveron (LGVN) Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel in Alzheimer’s Disease
Feb 28, 2025 04:04PM Longeveron (LGVN) Reports FY24 Results, Provides Business Update
Feb 18, 2025 09:26AM Longeveron (LGVN) Announces WHO Approval of “laromestrocel”
Jan 30, 2025 05:39PM Longeveron announces board member resignation
Nov 25, 2024 06:53AM H.C. Wainwright Reiterates Buy Rating on Longeveron (LGVN)
Nov 11, 2024 09:06AM Longeveron (LGVN) Appoints Devin Blass as CTO
Oct 29, 2024 10:03AM Longeveron (LGVN) Presents Lomecel-B Data for Alzheimer’s Disease Indication
Sep 4, 2024 07:25AM H.C. Wainwright Reiterates Buy Rating on Longeveron (LGVN)
Sep 3, 2024 09:02AM Longeveron (LGVN) Announces Positive Type C Meeting with FDA Regarding Pathway to BLA for Lomecel-B
Jul 29, 2024 06:53AM Longeveron (LGVN) PT Lowered to $10 at H.C. Wainwright
Jul 18, 2024 08:45AM Longeveron (LGVN) Announces 2.24M Share Offering at $4.025/sh
Jul 17, 2024 08:01AM Longeveron (LGVN) Granted FDA Fast Track Designation for Lomecel-B
Jul 10, 2024 07:31AM Longeveron (LGVN) Granted FDA Regenerative Medicine Advanced Therapy Designation for Lomecel-B
Jul 9, 2024 09:01AM Longeveron (LGVN) Appoints Neha Motwani to its Board
Jun 28, 2024 04:19PM Longeveron (LGVN) Files for 3.56M Share Offering by Selling Stockholders
Jun 17, 2024 08:39AM Longeveron (LGVN) Exercises $4.4M Worth of Warrants
Jun 11, 2024 09:01AM Longeveron (LGVN) Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B as a Potential Treatment for HLHS